Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB

by Ingrid Teige, Linda Mårtensson, Björn L. Frendéus
Published 2019-03-01

594 BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

by Laetitia Fend, Eric Quemeneur, Monika Semmrich, Jean-Baptiste Marchand, Matilda Rehn, Nathalie Silvestre, Linda Mårtensson, Johann Foloppe, Ingrid Teige, Björn Frendeus
Published 2020-11-01

725 Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy

by Monika Semmrich, Linda Mårtensson, Ingrid Teige, Björn Frendeus, Mathilda Kovacek, Petra Holmkvist, Carolin Svensson, Therese Blidberg, Carl Roos, Andres McAllister, Mimoza Demiri, Marie Borggren, Ingrid Karlsson
Published 2020-11-01

Domain binding and isotype dictate the activity of anti-human OX40 antibodies

by C Ian Mockridge, Kerry L Cox, Martin J Glennie, Mark S Cragg, Monika Semmrich, Linda Mårtensson, Ingrid Teige, Jordana Griffiths, Khiyam Hussain, Hannah L Smith, Theodore Sanders, Jinny Kim, Tatyana Inzhelevskaya, Chris A Penfold, Alison L Tutt, HT Claude Chan, Vikki English, Ruth F French, Bjorn L Frendeus, Jane E Willoughby
Published 2020-07-01